The news reporters obtained a quote from the research from Virginia University Medical Center, "EAMs associated with SpA include anterior uveitis (25-30%), psoriasis (10-25%) or inflammatory bowel disease (IBD) (5-10%) and cardiovascular manifestations. Peripheral arthritis occurs in approximately 30% of patients, especially in large joints, and shows an asymmetrical, oligoarticular pattern. Other common joint complaints are due to enthesitis, which manifest as extra-articular bony tenderness in areas such as the Achilles tendon. Acute anterior uveitis presents with acute pain, loss of vision and redness in one eye that usually subsides spontaneously after several weeks. Rapid treatment by an ophthalmologist is required to prevent synechiae formation which could ultimately result in glaucoma and blindness. Although less common, organ involvement in SpA can also be located in the heart, lungs or kidneys. The risk of cardiovascular events is increased in SpA. Cardiac manifestations can involve the aortic valve (1-10%) or the atrioventricular node and the risk of atherosclerotic events is increased in this group. Treatment of SpA includes physical exercise and nonsteroidal anti-inflammatory drugs (NSAIDs), and in case of peripheral arthritis, sulphasalazine can be added. When there is insufficient response to NSAIDs, tumor necrosis factor blockers, especially infliximab, etanercept, adalimumab and golimumab, are very effective in treating axial manifestations, arthritis, enthesitis and psoriasis. Anterior uveitis in SpA can be treated adequately by the ophthalmologist and in the case of refractory uveitis, treatment with adalimumab and infliximab seems to be more effective compared with etanercept. When IBD occurs with SpA, the use of NSAIDs should be minimized, except for celecoxib, and infliximab or adalimumab are preferred to etanercept. The incidence of atherosclerotic events or SpA-specific cardiac manifestations may be decreased by cardiovascular risk management or effective antirheumatic treatment."
According to the news reporters, the research concluded: "Overall it is important to realize that extra-articular manifestations frequently occur in patients with SpA and should be taken into account in the choice of treatment."
For more information on this research see: Management and evaluation of extra-articular manifestations in spondyloarthritis. Therapeutic Advances In Musculoskeletal Disease, 2012;4(6):413-22. (Sage Publications - www.sagepub.com/; Therapeutic Advances In Musculoskeletal Disease - tab.sagepub.com)
Our news correspondents report that additional information may be obtained by contacting I.E. van der Horst-Bruinsma, VU University Medical Center, Room 3A-64, PO Box 7057, 1007 MB Amsterdam, Netherlands.
Keywords for this news article include: Europe, Amsterdam, Arthritis, Cardiology, Netherlands, Eye Diseases, Ophthalmology, Joint Diseases, Uveal Diseases, Anterior Uveitis, Cardiovascular Research, Musculoskeletal Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.